Inamed CEO (Chief Executive Officer) defends silicone for breast implants
This article was originally published in Clinica
Executive Summary
The co-CEO of Inamed, one of the two major US manufacturers of breast implants and the company which inherited the liability for the failed soya oil filled implants used in Europe, has explained why he believes that silicone gel should be re-introduced as a filler in the US market. He has defended the company's clinical trials with the product and its attempt to gain US FDA approval, despite silicone's history of leakage and possible health damage.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.